Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Ticagrelor induces adenosine triphosphate release from human red blood cells.

Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D.

Biochem Biophys Res Commun. 2012 Feb 24;418(4):754-8. doi: 10.1016/j.bbrc.2012.01.093. Epub 2012 Jan 27.

PMID:
22306816
[PubMed - indexed for MEDLINE]
2.

Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.

van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA.

J Cardiovasc Pharmacol Ther. 2012 Jun;17(2):164-72. doi: 10.1177/1074248411410883. Epub 2011 Jun 22.

PMID:
21697355
[PubMed - indexed for MEDLINE]
3.

Ticagrelor: from discovery to Phase III clinical trial.

Siller-Matula JM, Jilma B.

Future Cardiol. 2010 Nov;6(6):753-64. doi: 10.2217/fca.10.89. Review.

PMID:
21142630
[PubMed - indexed for MEDLINE]
4.

Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.

Nylander S, Femia EA, Scavone M, Berntsson P, Asztély AK, Nelander K, Löfgren L, Nilsson RG, Cattaneo M.

J Thromb Haemost. 2013 Oct;11(10):1867-76. doi: 10.1111/jth.12360.

PMID:
23890048
[PubMed - indexed for MEDLINE]
5.

Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.

Zhang H, Liu J, Zhang L, Kong L, Yao H, Sun H.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3598-602. doi: 10.1016/j.bmcl.2012.04.050. Epub 2012 Apr 16.

PMID:
22546677
[PubMed - indexed for MEDLINE]
6.

Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ.

J Thromb Haemost. 2009 Sep;7(9):1556-65. doi: 10.1111/j.1538-7836.2009.03527.x. Epub 2009 Jun 23.

PMID:
19552634
[PubMed - indexed for MEDLINE]
7.

Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.

Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM.

J Am Coll Cardiol. 2013 Feb 19;61(7):723-7. doi: 10.1016/j.jacc.2012.11.032. Epub 2013 Jan 9.

PMID:
23312702
[PubMed - indexed for MEDLINE]
Free Article
8.

Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.

van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA.

Thromb Res. 2009 Nov;124(5):565-71. doi: 10.1016/j.thromres.2009.06.029. Epub 2009 Aug 18.

PMID:
19692114
[PubMed - indexed for MEDLINE]
9.

Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.

Iyú D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S.

Thromb Haemost. 2011 Jan;105(1):96-106. doi: 10.1160/TH10-07-0482. Epub 2010 Oct 12.

PMID:
20941457
[PubMed - indexed for MEDLINE]
10.

Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.

Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, Tantry U, Gurbel PA.

J Thromb Haemost. 2011 Sep;9(9):1730-7. doi: 10.1111/j.1538-7836.2011.04419.x.

PMID:
21707911
[PubMed - indexed for MEDLINE]
11.

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.

Butler K, Teng R.

J Clin Pharmacol. 2011 Jul;51(7):978-87. doi: 10.1177/0091270010379409. Epub 2010 Oct 6.

PMID:
20926753
[PubMed - indexed for MEDLINE]
12.

Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.

Serebruany VL.

Cardiology. 2010;117(3):231-3. doi: 10.1159/000322789. Epub 2011 Jan 5.

PMID:
21212672
[PubMed - indexed for MEDLINE]
13.

Ticagrelor for the treatment of arterial thrombosis.

Gurbel PA, Kereiakes DJ, Tantry US.

Expert Opin Pharmacother. 2010 Sep;11(13):2251-9. doi: 10.1517/14656566.2010.511175. Review.

PMID:
20707759
[PubMed - indexed for MEDLINE]
14.

Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.

Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ.

J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209-19. doi: 10.1177/1074248413511693. Epub 2014 Jan 10.

PMID:
24414167
[PubMed - indexed for MEDLINE]
15.

P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.

Crouch MA, Colucci VJ, Howard PA, Spinler SA.

Ann Pharmacother. 2011 Sep;45(9):1151-6. doi: 10.1345/aph.1Q141. Epub 2011 Aug 18.

PMID:
21852599
[PubMed - indexed for MEDLINE]
16.

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.

Zhou D, Andersson TB, Grimm SW.

Drug Metab Dispos. 2011 Apr;39(4):703-10. doi: 10.1124/dmd.110.037143. Epub 2010 Dec 22.

PMID:
21177984
[PubMed - indexed for MEDLINE]
Free Article
17.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
[PubMed - indexed for MEDLINE]
18.

Ticagrelor. Acute coronary syndromes: nothing new.

[No authors listed]

Prescrire Int. 2011 Oct;20(120):229-33.

PMID:
21970081
[PubMed - indexed for MEDLINE]
19.

Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.

Anderson SD, Shah NK, Yim J, Epstein BJ.

Ann Pharmacother. 2010 Mar;44(3):524-37. doi: 10.1345/aph.1M548. Epub 2010 Feb 2. Review.

PMID:
20124464
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.

Teng R, Butler K.

Eur J Clin Pharmacol. 2010 May;66(5):487-96. doi: 10.1007/s00228-009-0778-5. Epub 2010 Jan 21.

PMID:
20091161
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk